A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Trilostane
Gemfibrozil
The metabolism of Indacaterol can be decreased when combined with Gemfibrozil.
Trilostane
Metreleptin
The metabolism of Indacaterol can be increased when combined with Metreleptin.
Trilostane
Relugolix
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Relugolix.
Trilostane
Fostemsavir
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Fostemsavir.
Trilostane
Gallopamil
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Gallopamil.
Trilostane
Rilpivirine
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Rilpivirine.
Trilostane
Lidoflazine
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Lidoflazine.
Trilostane
Bencyclane
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Bencyclane.
Trilostane
Triclabendazole
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Triclabendazole.
Trilostane
Delafloxacin
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Delafloxacin.
Trilostane
Ebastine
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Ebastine.
Trilostane
Rupatadine
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Rupatadine.
Trilostane
Aranidipine
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Aranidipine.
Trilostane
Pinaverium
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Pinaverium.
Trilostane
Trimebutine
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Trimebutine.
Trilostane
Lurasidone
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Lurasidone.
Trilostane
Levocetirizine
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Levocetirizine.
Trilostane
Solifenacin
The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Indacaterol.
Trilostane
Sevoflurane
The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Indacaterol.
Trilostane
Orphenadrine
The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Indacaterol.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3